CareDx Issues Statement in Patent Infringement Case
January 26 2024 - 9:45PM
Business Wire
CareDx Found to Have Not Infringed on Patent
‘180 CareDx Intends to Seek Judicial Review of Decision and
Monetary Damages on Patent ‘544 No Impact to Patient or Physician
Access to AlloSure or AlloMap Testing
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on
the discovery, development, and commercialization of clinically
differentiated, high-value healthcare solutions for transplant
patients and caregivers – today announced the jury verdict in the
patent litigation brought by Natera, Inc. (Nasdaq: NTRA).
CareDx was found to have not infringed on Natera patent
10,655,180 (the ‘180 patent) and found to have infringed on Natera
patent 11,111,544 (the ‘544 patent). During pre-trial motions, the
Court dismissed an additional patent asserted by Natera against
CareDx. The District of Delaware jury awarded Natera damages
including lost profits of $83,679,521 and past royalty of
$12,535,500 for alleged infringement by AlloSure, occurring from
September 2021 through August 2023. CareDx intends to seek judicial
review of the verdict.
Today’s decision does not affect access and availability to
CareDx’s current offerings, including AlloSure® or AlloMap®. There
is no motion pending for injunctive relief.
CareDx will continue to improve transplant patient care by
providing innovative solutions throughout the entire patient
journey.
About CareDx – The Transplant Company
CareDx, Inc., headquartered in Brisbane, California, is a
leading precision medicine solutions company focused on the
discovery, development, and commercialization of clinically
differentiated, high-value healthcare solutions for transplant
patients and caregivers. CareDx offers testing services, products,
and digital healthcare solutions along the pre- and post-transplant
patient journey and is the leading provider of genomics-based
information for transplant patients. For more information, please
visit: www.CareDx.com.
Forward Looking Statements
This press release includes forward-looking statements related
to CareDx, Inc., including statements regarding the jury verdict in
the patent infringement case brought by Natera, the impact of the
verdict on CareDx and CareDx’s plans to seek judicial review of the
decision regarding the ‘544 patent and monetary damages. These
forward-looking statements are based upon information that is
currently available to CareDx and its current expectations, speak
only as of the date hereof, and are subject to risks and
uncertainties that could cause actual results to differ materially
from those projected, including risks that the impact of the
verdict differs from CareDx’s estimates; general economic and
market factors; and other risks discussed in CareDx’s filings with
the SEC, including the Annual Report on Form 10-K for the fiscal
year ended December 31, 2022 filed by CareDx with the SEC on
February 27, 2023, the quarterly report on Form 10-Q for the
quarter ended March 31, 2023 filed by CareDx with the SEC on May
10, 2023, the quarterly report on Form 10-Q for the quarter ended
June 30, 2023 filed by CareDx with the SEC on August 8, 2023, the
quarterly report on Form 10-Q for the quarter ended September 30,
2023 filed by CareDx with the SEC on or about November 8, 2023, and
other reports that CareDx has filed with the SEC. Any of these may
cause CareDx’s actual results, performance, or achievements to
differ materially and adversely from those anticipated or implied
by CareDx’s forward-looking statements. CareDx expressly disclaims
any obligation, except as required by law, or undertaking to update
or revise any such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240126667014/en/
CareDx, Inc. Media Relations Anna Czene 818-731-2203
aczene@caredx.com Investor Relations Greg Chodaczek
investor@caredx.com
CareDx (NASDAQ:CDNA)
Historical Stock Chart
From Apr 2024 to May 2024
CareDx (NASDAQ:CDNA)
Historical Stock Chart
From May 2023 to May 2024